ES2236415T3 - Inhibicion de la histona desacetilasa para el tratamiento de la hipertrofia cardiaca. - Google Patents

Inhibicion de la histona desacetilasa para el tratamiento de la hipertrofia cardiaca.

Info

Publication number
ES2236415T3
ES2236415T3 ES02021676T ES02021676T ES2236415T3 ES 2236415 T3 ES2236415 T3 ES 2236415T3 ES 02021676 T ES02021676 T ES 02021676T ES 02021676 T ES02021676 T ES 02021676T ES 2236415 T3 ES2236415 T3 ES 2236415T3
Authority
ES
Spain
Prior art keywords
hdac
tsa
administration
medication
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02021676T
Other languages
English (en)
Spanish (es)
Inventor
Michael R. Bristow
Carlin Long
Timothy A. Mckinsey
Eric N. Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
University of Texas System
University of Texas at Austin
University of Colorado Colorado Springs
Original Assignee
University of Colorado Boulder
University of Texas System
University of Texas at Austin
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder, University of Texas System, University of Texas at Austin, University of Colorado Colorado Springs filed Critical University of Colorado Boulder
Application granted granted Critical
Publication of ES2236415T3 publication Critical patent/ES2236415T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
ES02021676T 2001-09-27 2002-09-27 Inhibicion de la histona desacetilasa para el tratamiento de la hipertrofia cardiaca. Expired - Lifetime ES2236415T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32531101P 2001-09-27 2001-09-27
US325311P 2001-09-27
US33404101P 2001-10-31 2001-10-31
US334041P 2001-10-31

Publications (1)

Publication Number Publication Date
ES2236415T3 true ES2236415T3 (es) 2005-07-16

Family

ID=26984878

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02021676T Expired - Lifetime ES2236415T3 (es) 2001-09-27 2002-09-27 Inhibicion de la histona desacetilasa para el tratamiento de la hipertrofia cardiaca.

Country Status (8)

Country Link
US (4) US6706686B2 (enExample)
EP (1) EP1297851B1 (enExample)
JP (2) JP2003238445A (enExample)
AT (1) ATE287731T1 (enExample)
DE (1) DE60202727T2 (enExample)
DK (1) DK1297851T3 (enExample)
ES (1) ES2236415T3 (enExample)
PT (1) PT1297851E (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028020A2 (en) * 1998-11-10 2000-05-18 Board Of Regents, The University Of Texas System Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070104688A1 (en) * 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
US20040171118A1 (en) * 2003-02-13 2004-09-02 City Of Hope Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
MXPA05012619A (es) * 2003-05-21 2006-02-08 Univ Texas Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
JP2007504131A (ja) * 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050283841A1 (en) * 2004-02-02 2005-12-22 Mckinsey Timothy A Inhibition of protein kinase C-related kinase (PRK) as a treatment for cardiac hypertrophy and heart failure
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
US20050288215A1 (en) * 2004-04-05 2005-12-29 Mckinsey Timothy A Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
EP1740945B1 (en) 2004-04-07 2018-09-19 Ncardia AG Non-invasive, in vitro functional tissue assay systems
ES2354997T3 (es) 2004-05-11 2011-03-21 Axiogenesis Ag Ensayo para el descubrimiento de fármacos basado en células diferenciadas in vitro.
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
US20060110390A1 (en) * 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7772245B2 (en) 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP1901764A1 (en) * 2005-07-14 2008-03-26 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
WO2007011626A2 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20090012066A1 (en) * 2005-08-10 2009-01-08 Novartis Ag Method of Use of Deacetylase Inhibitors
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
US7863414B2 (en) 2005-11-18 2011-01-04 The Board Of Regents Of The University Of Texas Systems Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20100226857A1 (en) * 2006-03-29 2010-09-09 Jeannine Strobl Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites
KR20080108156A (ko) * 2006-04-06 2008-12-11 노파르티스 아게 유기 화합물의 조합물
AU2007238600B2 (en) * 2006-04-13 2012-01-19 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
WO2007145704A2 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
CN101801994A (zh) * 2006-12-29 2010-08-11 格洛斯特制药公司 制备Romidepsin
AU2007342030B2 (en) * 2006-12-29 2013-08-15 Celgene Corporation Romidepsin-based treatments for cancer
US9884031B2 (en) * 2007-05-09 2018-02-06 The Trustees Of The University Of Pennsylvania Use of HDAC inhibitors for treatment of cardiac rhythm disorders
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
WO2009048540A1 (en) * 2007-10-05 2009-04-16 U.S. Department Of Veterans Affairs Office Of General Counsel - Psg Iv (024) Method and composition for treating heart failure
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
WO2010039697A2 (en) * 2008-09-30 2010-04-08 Gilead Sciences, Inc. Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
WO2011032088A1 (en) 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
EP2593123B1 (en) 2010-07-12 2019-09-04 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
RS58895B1 (sr) 2010-10-13 2019-08-30 Medivir Ab Farmaceutska formulacija za inhibitore histonske deacetilaze
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CA3156303A1 (en) * 2019-10-03 2021-04-08 Tenaya Therapeutics, Inc. 5-fluoronicotinamide derivatives and uses thereof
WO2021127643A1 (en) 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
CN116942822A (zh) * 2023-06-12 2023-10-27 深圳大学 Hdac2在治疗室性心律失常中的应用
CN118766882B (zh) * 2024-09-12 2025-02-21 北京大学第三医院（北京大学第三临床医学院） 用于治疗心血管疾病的制剂及其应用和制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5968981A (en) * 1995-07-28 1999-10-19 The Regents Of The University Of California Retinoid suppression of ventricular muscle cell hypertrophy
JP2002528391A (ja) 1998-10-19 2002-09-03 メチルジェン，インク． 組合せ治療による遺伝子発現の修飾
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
CA2366408A1 (en) 1999-05-03 2000-11-30 Methylgene, Inc. Inhibition of histone deacetylase
JP2003507076A (ja) 1999-08-20 2003-02-25 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 心臓の遺伝子発現の調節におけるｈｄａｃ４およびｈｄａｃ５
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
WO2001017514A1 (en) * 1999-09-03 2001-03-15 The Salk Institute For Biological Studies Modulation of gene expression by modulating histone acetylation
JP2003508501A (ja) 1999-09-07 2003-03-04 コンジュケム，インコーポレーテッド 生物学的結合のための肺送達
ES2287033T3 (es) 1999-09-08 2007-12-16 Sloan-Kettering Institute For Cancer Research Estructura cristalina de una desacetilasa e inhibidores de la misma.
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
DE60026733T2 (de) 1999-12-08 2006-11-02 AXYS Pharmaceuticals, Inc., South San Francisco Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
CA2408385A1 (en) 2000-03-24 2001-09-24 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
CA2404002A1 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
AU9013101A (en) 2000-09-29 2002-04-22 Prolifix Ltd Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
JP2004509941A (ja) 2000-09-29 2004-04-02 プロリフィクス　リミテッド Ｈｄａｃインヒビターとしてのアミド結合を含むカルバミン酸化合物
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
JP2004520027A (ja) 2000-12-20 2004-07-08 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ関連遺伝子およびタンパク質
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

Also Published As

Publication number Publication date
US6946441B2 (en) 2005-09-20
DE60202727T2 (de) 2005-12-29
US20040186049A1 (en) 2004-09-23
DE60202727D1 (de) 2005-03-03
JP2003238445A (ja) 2003-08-27
PT1297851E (pt) 2005-06-30
US20030144340A1 (en) 2003-07-31
US20060069014A1 (en) 2006-03-30
EP1297851A1 (en) 2003-04-02
US6706686B2 (en) 2004-03-16
DK1297851T3 (da) 2005-05-30
JP2010001311A (ja) 2010-01-07
ATE287731T1 (de) 2005-02-15
EP1297851B1 (en) 2005-01-26
US20060025333A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
ES2236415T3 (es) Inhibicion de la histona desacetilasa para el tratamiento de la hipertrofia cardiaca.
US20250360129A1 (en) Compositions and methods of using tyrosine kinase inhibitors
Wing et al. Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks
Johnson et al. Thermoregulatory and thermal control in the human cutaneous circulation
Santos et al. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system
AU2005277384B2 (en) PDE5 inhibitor compositions and methods for treating cardiac indications
US8883842B2 (en) Use of HDAC inhibitors for the treatment of myeloma
EP2968238A1 (en) Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist
WO2016100385A2 (en) Compounds, compositions and methods for treating or preventing neurodegenerative disorders
WO2014066419A2 (en) Methods for reducing risks associated with heart failure and factors associated therewith
US20110171196A1 (en) Methods of treatment and uses for camkii and its interaction with hdacs and calpain
WO2007143630A2 (en) Treatment of neurofibromatosis with hsp90 inhibitors
Jiang et al. Loss of USP22 alleviates cardiac hypertrophy induced by pressure overload through HiF1-α-TAK1 signaling pathway
Zhou et al. Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3
US20100004248A1 (en) Use of a Nitric Oxide Synthase Modulator for the Treatment of Cardiac Indications
EP1605262A1 (en) Method of identifying inhibitors of cardiac hypertrophy
US20140296143A1 (en) Angiotensin-(1-7) As A Chemoprevention Agent
Xu et al. Ang II enhances atrial fibroblast autophagy and promotes atrial remodeling through the AT1-ERK-mTOR signaling pathway
Liu The Physiological and Pathological Roles of PKA Regulatory Subunit 1α in the Heart
ES2961003T3 (es) D-Arg-2'6'-Dmt-Lys-Phe-NH2 para su uso en el tratamiento o la prevención del síndrome de Sengers
Castro-Rivera Adenosine A2A Receptor Stimulation Enhances Mitochondrial Metabolism and Mitigates Reactive Oxygen Species-Mediated Mitochondrial Injury in the Context of Osteoarthritis
Biala MOLECULAR MECHANISMS OF HYPERTENSION-INDUCED HEART FAILURE
WO2016166291A1 (en) Materials and methods for treatment of pulmonary hypertension